SignatureFD
RPRX icon

SignatureFD’s Royalty Pharma RPRX Stock Holding History

SignatureFD’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$281K Buy
4,818
+569
+13% +$33.6K ﹤0.01% 972
2026
Q2 		$238K Buy
4,249
+913
+27% +$47.5K ﹤0.01% 1005
2026
Q1 		$160K Buy
3,336
+58
+2% +$2.54K ﹤0.01% 1115
2025
Q4 		$127K Buy
3,278
+182
+6% +$6.94K ﹤0.01% 1203
2025
Q3 		$109K Sell
3,096
-62
-2% -$2.24K ﹤0.01% 1250
2025
Q2 		$114K Buy
3,158
+464
+17% +$15.4K ﹤0.01% 1184
2025
Q1 		$83.9K Buy
2,694
+123
+5% +$3.9K ﹤0.01% 1309
2024
Q4 		$65.6K Sell
2,571
-1,283
-33% -$34K ﹤0.01% 1430
2024
Q3 		$109K Sell
3,854
-1,840
-32% -$51K ﹤0.01% 1177
2024
Q2 		$150K Sell
5,694
-4,920
-46% -$136K ﹤0.01% 961
2024
Q1 		$322K Sell
10,614
-272
-2% -$8.02K 0.01% 656
2023
Q4 		$306K Buy
10,886
+5,007
+85% +$138K 0.01% 636
2023
Q3 		$160K Buy
5,879
+4,335
+281% +$129K ﹤0.01% 823
2023
Q2 		$47.5K Sell
1,544
-686
-31% -$23.2K ﹤0.01% 1465
2023
Q1 		$80.3K Buy
2,230
+1,699
+320% +$63K ﹤0.01% 1150
2022
Q4 		$21K Sell
531
-39
-7% -$1.63K ﹤0.01% 1779
2022
Q3 		$23K Buy
570
+131
+30% +$5.6K ﹤0.01% 1678
2022
Q2 		$18K Sell
439
-249
-36% -$10.2K ﹤0.01% 1836
2022
Q1 		$27K Buy
688
+241
+54% +$9.46K ﹤0.01% 1696
2021
Q4 		$18K Buy
447
+377
+539% +$14.6K ﹤0.01% 1838
2021
Q3 		$3K Buy
70
+18
+35% +$700 ﹤0.01% 2551
2021
Q2 		$2K Buy
52
+5
+11% +$213 ﹤0.01% 2613
2021
Q1 		$2K Buy
47
+34
+262% +$1.61K ﹤0.01% 2522
2020
Q4 		$1K Buy
+13
New +$552 ﹤0.01% 2475

Other funds holding RPRX

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Hosking Partners
Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return
Kepler Cheuvreux
Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return
Kirr Marbach & Co
Kirr Marbach & Co Columbus, Indiana $530M AUM 14.37% 1-Year Est. Return
Triasima Portfolio Management
Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

SignatureFD's RPRX Position: Q3 2026 in Review

SignatureFD increased its Royalty Pharma (RPRX) stake by 13% in Q3 2026, buying an estimated $33.6K and bringing the position to 4,818 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #972.

SignatureFD first reported a position in RPRX in Q4 2020 and has held it in 24 quarters since. The position peaked at $322K in Q1 2024. 129 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • SignatureFD held 4,818 shares of Royalty Pharma worth $281K as of Q3 2026.
  • SignatureFD bought 569 Royalty Pharma shares in Q3 2026, an estimated $33.6K.
  • Royalty Pharma made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #972 holding.
  • SignatureFD first reported a position in Royalty Pharma in Q4 2020 and has held it in 24 quarters since.
  • SignatureFD's Royalty Pharma position peaked at $322K in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.